IL13Rα2 is involved in the progress of renal cell carcinoma through the JAK2/FOXO3 pathway
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Mi-Ae | - |
dc.contributor.author | Lee, Jongsung | - |
dc.contributor.author | Lee, Chang Min | - |
dc.contributor.author | Park, Ho Sung | - |
dc.contributor.author | Jang, Kyu Yun | - |
dc.contributor.author | Park, See-Hyoung | - |
dc.date.accessioned | 2021-05-07T00:40:14Z | - |
dc.date.available | 2021-05-07T00:40:14Z | - |
dc.date.created | 2021-05-03 | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 2075-4426 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80939 | - |
dc.description.abstract | Previously, we reported a close relationship between type II IL4Rα and IL13Rα1 complex and poor outcomes in renal cell carcinoma (RCC). In this study, we investigated the clinicopathologi-cally significant oncogenic role of IL13Rα2, a kind of the independent receptor for IL13, in 229 RCC patients. The high expression of IL13Rα2 was closely related to relapse-free survival in specific cancers in univariate and multivariate analysis. Then, the oncogenic role of IL13Rα2 was evaluated by performing in vitro assays for cell proliferation, cell cycle arrest, and apoptosis in A498, ACHN, Caki1, and Caki2, four kinds of RCC cells after transfection of siRNA against IL13Rα2. Cell proliferation was suppressed, and apoptosis was induced in A498, ACHN, Caki1, and Caki2 cells by knockdown of IL13Rα2. Interestingly, the knockdown of IL13Rα2 decreased the phosphorylation of JAK2 and increased the expression of FOXO3. Furthermore, the knockdown of IL13Rα2 reduced the protein interaction among IL13Rα2, phosphorylated JAK2, and FOXO3. Since phosphorylation of JAK2 was regulated by IL13Rα2, we tried to screen a novel JAK2 inhibitor from the FDA-approved drug library and selected telmisartan, a clinically used medicine against hypertension, as one of the strongest candidates. Telmisartan treatment decreased the cell proliferation rate and increased apoptosis in A498, ACHN, Caki1, and Caki2 cells. Mechanistically, telmisartan treatment decreased the phosphorylation of JAK2 and increased the expression of FOXO3. Taken together, these results suggest that IL13Rα2 regulates the progression of RCC via the JAK2/FOXO3-signaling path pathway, which might be targeted as the novel therapeutic option for RCC patients. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | Journal of Personalized Medicine | - |
dc.title | IL13Rα2 is involved in the progress of renal cell carcinoma through the JAK2/FOXO3 pathway | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000643117200001 | - |
dc.identifier.doi | 10.3390/jpm11040284 | - |
dc.identifier.bibliographicCitation | Journal of Personalized Medicine, v.11, no.4 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85104677549 | - |
dc.citation.title | Journal of Personalized Medicine | - |
dc.citation.volume | 11 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Kang, Mi-Ae | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | FOXO3 | - |
dc.subject.keywordAuthor | IL13Rα2 | - |
dc.subject.keywordAuthor | JAK2 | - |
dc.subject.keywordAuthor | Renal cell carcinoma | - |
dc.subject.keywordAuthor | Telmisartan | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.